LongevityBiz Newsletter 13 · November 10, 2026
Market signals
An existing practice turns a baseline blood test into a recurring longevity service.
Ceribell adds reimbursable delirium monitoring to an established hospital platform.
Caris shows molecular profiling becoming a billion-dollar precision-medicine business.
A longevity supplement clears a more meaningful human-evidence threshold.
Superpower bundles peptide prescribing, blood testing and follow-up into one service.
1. A baseline blood test becomes the foundation for a new longevity service
Nightingale Health’s blood-based disease-risk test will anchor a new longevity membership at S-Thetics, an established doctor-led clinic in Beaconsfield, England.
S-Thetics already has clinical space, staff and patients who are investing in how they age. It is now using an outside laboratory partner to expand from aesthetic medicine and skin health into preventive care. Members receive a baseline test estimating 10-year risk for five chronic diseases, a physician-reviewed plan and repeat testing to measure change.
That is the signal: a practice does not have to become a large longevity center to add a credible service. It can retain the patient relationship and clinical follow-up while a specialist partner supplies the testing capability. The resulting membership can create recurring revenue while giving patients something more useful than a one-time report.
Neither company has disclosed price, enrollment or economics. What matters next is whether existing patients convert, remain engaged and act on the results. If that works, the model could be repeated by other concierge, aesthetics and specialty practices with trusted patient relationships and existing clinical capacity.
2. Ceribell turns one hospital platform into a broader neurological service
Ceribell commercially launched AI-enabled delirium monitoring on the point-of-care EEG system hospitals already use for seizure detection. One headband can now support both functions, and CMS has established a New Technology Add-on Payment of up to $2,171 for an eligible Medicare inpatient case, subject to its rules.
Delirium can be difficult to recognize through intermittent bedside assessments. Continuous monitoring could identify neurological change earlier, although Ceribell’s decision-making claims come from an early hospital pilot rather than broad outcomes data.
The commercial model is unusually concrete: installed hardware, subscription software, another clinical use and a reimbursement pathway. Ceribell reported 747 active accounts, $29.3 million in quarterly revenue and a 90% gross margin, while remaining unprofitable. The next test is whether delirium monitoring increases account utilization and proves valuable beyond the initial payment incentive.
3. Molecular profiling becomes a billion-dollar precision-medicine business
Caris Life Sciences reported $275.4 million in third-quarter revenue, up 27% from a year earlier, after completing approximately 61,500 clinical cases involving more than 358,000 oncology tests. The company raised its 2026 revenue guidance to $1.04 billion–$1.05 billion.
Caris does not need to call itself a longevity company to be central to longer, healthier lives. Cancer takes healthy years through both the disease and treatments that fail. Molecular profiling can help match a tumor to therapy. Caris has launched therapeutic-response monitoring, while its residual-disease assay—intended to detect whether cancer remains or returns—was still targeted for launch later in 2026.
Caris is trying to extend one infrastructure from treatment selection into response monitoring, recurrence and eventually earlier detection. It reported a 66% gross margin and $15.3 million in net income, but used $22.2 million in operating cash as expansion and research spending increased. The opportunity is a continuing precision-oncology relationship—not a collection of disconnected tests.
4. A longevity supplement clears a more meaningful evidence threshold
In a randomized, double-blind university-led trial supported by NOVOS, 43 of 61 enrolled participants completed six months of follow-up. Compared with placebo, the supplement improved the trial’s primary measure of blood-vessel function and produced favorable differences in arterial stiffness and systolic blood pressure.
The study measured vascular efficacy, not lifespan or clinical events. Its importance is that NOVOS can now point to measurable human outcomes under blinded conditions rather than rely only on ingredients, testimonials or biological-age marketing.
Efficacy can become a selling point. Better evidence can earn clinician trust, strengthen distribution and distinguish a product in a crowded supplement market. It also gives practices a more defensible basis for selecting what belongs in a program. Replication would make that advantage substantially stronger.
5. Superpower turns peptides into a monitored care program
Superpower opened pre-orders for a clinician-directed peptide service that combines prescribing, an initial blood panel, regular check-ins, laboratory monitoring and pharmacy fulfillment. Shipping is expected to begin at the end of November.
The business is not simply access to BPC-157, TB-500 or MOTS-C. Superpower is wrapping treatments already attracting demand—but backed by limited human evidence—inside a continuing care relationship. Its platform starts with testing, adds clinician review and prescription, and keeps the member through monitoring and support.
That creates recurring revenue across membership, care and medication while offering a more organized alternative to consumers buying peptides from unsupervised sources. It also puts Superpower directly against longevity and concierge practices that could assemble similar programs through laboratory and pharmacy partners. The peptides are compounded medications rather than FDA-approved drugs. The business opportunity is assembling fragmented demand into a monitored care relationship. Whether that model endures will depend on clinical evidence, patient outcomes, pharmacy quality and a regulatory pathway that remains uncertain.
Three more things we’re watching
Beyond this week’s five signals, three developments deserve a closer watch.
GLP-1 update: Hims turns the prescription into a continuing care program
Lilly and Hims & Hers agreed to offer FDA-approved Zepbound and Foundayo through the Hims platform. Eligible patients can complete a telehealth consultation and, if prescribed, receive medicine at home. Self-pay prices begin at $299 per month for Zepbound and $149 for Foundayo.
The competitive product is no longer just the drug. Hims combines the consultation, prescription, home delivery, care-team access, nutrition guidance and follow-up in one relationship.
That is the challenge—and opportunity—for independent practices. They cannot compete merely by writing the same prescription. They can compete by knowing the patient better and delivering a stronger metabolic-health program around the medicine: appropriate selection, body composition, risk monitoring, side-effect management, nutrition and a plan for maintaining health after weight loss. The winner may be whoever keeps the patient engaged long enough to turn weight loss into lasting health improvement.
Since we last looked: Elucid adds evidence behind its cardiac-imaging tool
In NL12, we covered the FDA clearance of Elucid’s FFR-IQ software. The company has now reported ELUCIDATE validation results: 92.9% vessel-level accuracy against invasive fractional flow reserve across 491 vessels from 347 patients at 11 U.S. and European institutions.
The results strengthen the case that an existing coronary CT can support treatment decisions rather than provide anatomy alone. Presented at a conference and announced by the company, they do not establish better outcomes or routine adoption. For smaller practices, the route is coordination with imaging and cardiology partners—not scanner ownership.
Healthspan Destroyers Watch: Alzheimer’s genetics points beyond amyloid
The largest Alzheimer’s genetic study to date, involving approximately 2.8 million people, identified 48 previously unrecognized risk regions. More importantly, the findings reinforced the role of microglia—the brain’s immune cells—and revealed additional clues about vulnerable neurons and potential drug targets. Researchers also found 17 genes in the new regions that interact with drugs already approved for other conditions.
Most disease-modifying Alzheimer’s treatments have concentrated on amyloid. This research strengthens the case for regulating brain immune responses and protecting vulnerable neurons. It also estimates that common genetic variants account for about 16% of differences in underlying Alzheimer’s risk, substantially above earlier estimates.
The research map is not privately owned. The authors released summary statistics for multi-ancestry and ancestry-specific analyses, while analysis code is available through GitHub and Zenodo. Big pharmaceutical companies, specialist biotechs and computational drug-discovery platforms can all interrogate the findings; individual-level data remain controlled by the contributing research cohorts.
Near-term value will go to organizations that can turn a public lead into proprietary validation, a compound, a biomarker or a trial. Large drugmakers have the capital and development machinery to move quickly, while smaller neuroinflammation and neuroprotection companies may build focused programs that can later be licensed. The 17 drug–gene connections offer a starting list for repurposing work, not proof that any existing medicine prevents Alzheimer’s.
Coordination becomes the advantage
S-Thetics combines an outside laboratory with its patient relationship. Ceribell adds another reimbursable service to installed hardware. Caris extends one molecular infrastructure across more of the cancer journey. NOVOS tries to make efficacy a product advantage. Superpower assembles testing, prescribing, pharmacy fulfillment and follow-up around treatments already attracting demand.
The scalable model is not owning everything. It is knowing what to build, what to buy, what to deliver through partners, what to refer—and when not to proceed. The durable businesses will connect specialized capabilities into credible care, sound economics and measurable results.
Know someone who follows the business of longer, healthier lives? Forward this issue to them.
More from LongevityBiz
Find and compare 300 companies across the longevity economy. Explore laboratories, diagnostics, clinical services, infrastructure and other capabilities using category browsing or everyday business questions.
Rick’s Deep Dives
Read Rick Polito’s original reporting on the people and business models shaping longevity care.
Catch up on earlier issues of the free LongevityBiz newsletter.
© 2026 The Longevity Biz, LLC.